VIOLETTE: A randomized phase II study to assess the DNA damage response inhibitors AZD6738 or AZD1775 in combination with olaparib (Ola) versus Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC).

Andrew Tutt,Christine Stephens,Paul Frewer,Andrew Pierce,Joon Rhee,Sarah Edgington,Lone Ottesen,Mei-Lin Ah-See,Simon J. Hollingsworth,Emma Dean

VIOLETTE: A randomized phase II study to assess the DNA damage response inhibitors AZD6738 or AZD1775 in combination with olaparib (Ola) versus Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC).

2019

Andrew Tutt
Christine Stephens
Paul Frewer
Andrew Pierce
Joon Rhee
Sarah Edgington
Lone Ottesen
Mei-Lin Ah-See
Simon J. Hollingsworth
Emma Dean

TPS1112Background: TNBC comprises ≈15% of invasive breast cancer cases and alterations in BRCA1/2 are associated with ≈5% of all BCs. Ola (a poly ADP-ribose polymerase inhibitor [PARPi]) is approve...

Keywords:

DNA damage
Olaparib
Phases of clinical research
Triple-negative breast cancer
Pathology
Oncology
Medicine
Internal medicine
polymerase inhibitor
in patient
Breast cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations